查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363076

美国临床肿瘤学下一代定序市场规模、份额、趋势分析报告：按工作流程、按技术、按应用、按最终用途、细分趋势，2023-2030 年

U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End-use, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国临床肿瘤学下一代定序市场成长与趋势

Grand View Research, Inc. 的最新报告显示，到 2030 年，美国临床肿瘤学下一代定序市场预计将达到 5.04 亿美元。

预计2023年至2030年该市场将以15.1%的年复合成长率扩张。由于行业参与者之间的竞争加剧、领域的技术进步以及基因序列测定成本的降低，预计该市场在 2023 年至 2030 年的预测期内将显着增长。

日益激烈的市场竞争以及基于肿瘤学领域次世代定序仪的创新解决方案的推出预计将在预测期内推动市场成长。例如，2023年2月，癌症筛检和诊断测试公司Exact Sciences Corp.在美国推出了其治疗选择测试—OncoExTra。这是一种基于定序的下一代基因组测试，可以帮助癌症治疗。帮助理解和表征癌症肿瘤。此外，各公司正在共同努力，专注于次世代定序的进步，以获得该行业的竞争优势。例如，2020 年 1 月，市场上的两家主要企业Illumina, Inc. 和 F. Hoffmann-La Roche Ltd. 宣布 NGS 具有改变癌症检测、诊断、风险预测、治疗和监测的潜力。签署了一份为期15 年的合约来发现我的性取向。

此外，还发表了有关 NGS 在肿瘤学和癌症治疗中的应用的各种论文和研究。例如，2023 年 6 月，《柳叶刀》发表了一篇关于 NGS 测试在癌症患者中的真实结果和效用的论文。此外，2023 年 6 月，美国临床肿瘤学会发表了一项关于 NGS 检测对美国晚期癌症管理的临床影响的研究。此类研究正在帮助研究人员和临床医生提高对 NGS 在癌症治疗中的应用的认识和知识。

此外，由于定序成本的降低，预计预测期内临床肿瘤学下一代定序市场的成长将会成长。透过增加平行定序和运作多个流动槽以提高定序容量，可以降低 NGS 的成本，而不会增加相关成本。预计这些因素将在预测期内增加美国的市场需求。

美国临床肿瘤学下一代定序市场报告亮点

  • 根据工作流程细分，NGS 定序在 2022 年的收益占有率最大，达到 55.6%。该领域的主导地位归因于癌症测序项目的增加和该领域的技术进步。
  • 从技术来看，标靶定序和重测序占据市场主导地位，2022 年收益占有率为 72.9%。这是由于标靶化组合的使用增加及其在识别癌症肿瘤方面的效率。
  • 从应用来看，筛检领域在美国临床肿瘤NGS市场占据主导地位，2022年收益占有率为80.6%。
  • 根据最终用途，实验室细分市场在 2022 年美国临床肿瘤 NGS 市场中占据最大份额，为 64.4%。该领域的主导地位是由于癌症治疗的研发活动不断增加。

目录

第1章调查方法与范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 产业分析工具
    • SWOT 分析；按因素（政治/法律、经济/技术）
    • 波特五力分析
    • COVID-19感染疾病的影响分析

第4章美国临床肿瘤下一代定序市场分类：技术预估与趋势分析

  • 美国临床肿瘤NGS市场：技术变迁分析
  • 依技术
  • 全基因组序列测定
    • 全基因组定序市场，2018-2030
  • 全外显子定序
    • 全外显子定序市场，2018-2030
  • 标靶定序和重定序
    • 2018-2030 年目标定序与重定序市场

第5章美国临床肿瘤次世代定序市场分类：工作流程估算与趋势分析

  • 美国临床肿瘤NGS市场：工作流程变化分析
  • 按工作流程
  • 5 NGS预测序
  • NGS定序
  • NGS资料分析

第6章美国临床肿瘤二代定序市场分类：应用预估及趋势分析

  • 美国临床肿瘤NGS市场：应用变化分析
  • 按最终用途
  • 筛选
    • 2018-2030 年美国临床肿瘤学 NGS 市场筛选
    • 散发性癌症
    • 遗传性癌症
  • 伴随诊断
    • 美国临床肿瘤学 NGS 伴随诊断市场，2018-2030 年
  • 其他诊断
    • 美国临床肿瘤学 NGS 其他诊断市场，2018-2030 年

第7章美国临床肿瘤学下一代定序市场分类：最终用途估计和趋势分析

  • 美国临床肿瘤学 NGS 市场：最终用途变异分析
  • 按最终用途
  • 医院
  • 诊所
  • 实验室

第8章竞争形势

  • 公司分类
  • 策略规划
  • 公司简介/名单
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Myriad Genetics, Inc.
    • Beijing Genomics Institute（BGI）
    • QIAGEN
    • Perkin Elmer, Inc.
    • PacBio
    • Oxford Nanopore Technologies
    • PerkinElmer Inc
    • Macrogen, Inc
Product Code: GVR-1-68038-168-9

U.S. Clinical Oncology Next Generation Sequencing Market Growth & Trends:

The U.S. clinical oncology next generation sequencing market is expected to reach USD 500.4 million by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 15.1% from 2023 to 2030. The market is expected to increase at a significant rate during the forecast period from 2023 to 2030 owing to the increasing competition among the industry players, technological advances in the field and decreasing costs for genetic sequencing.

The increasing market competition and the launch of innovative solutions based on next generation sequencing in the oncology field are expected to fuel market growth over the forecast period. For instance, in February 2023, Exact Sciences Corp., a cancer screening and diagnostic testing company, introduced the therapy selection test -OncoExTra in the U.S. It is a next-generation sequencing-based genomic test to help in cancer care. It helps in understanding and characterizing cancer tumors. Moreover, to gain a competitive edge in the industry, companies are collaborating and focusing on advancing in the next generation sequencing. For instance, in January 2020, the two key players operating in the market, Illumina, Inc and F. Hoffmann-La Roche Ltd, signed a 15-year agreement to discover NGS's potential to transform cancer detection, diagnosis, risk prediction, treatment, and monitoring.

Moreover, various articles and studies are being published on the use of NGS in oncology and cancer treatments. For instance, in June 2023, the Lancet published an article on real-world outcomes and the usefulness of NGS testing in cancer patients. Furthermore, in June 2023, the American Society Of Clinical Oncology published a study on the clinical impact of NGS tests for managing advanced cancer in the U.S. Such studies help researchers and clinicians increase awareness and knowledge about the use of NGS for cancer treatments.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is expected to witness growth due to reduced sequencing costs. The costs of NGS can be reduced by increasing parallel sequencing and running multiple flow cells to increase sequencing capacity without raising the costs associated with it. These factors are anticipated to boost the market demand over the forecast period in the U.S.

U.S. Clinical Oncology Next Generation Sequencing Market Report Highlights:

  • NGS sequencing accounted for the largest revenue share of 55.6% in 2022 based on the workflow segment. The dominance of the segments is due to the increasing number of cancer sequencing projects and technological advances in the field.
  • Based on the technology, targeted sequencing & resequencing dominated the market with a revenue share of 72.9% in 2022. This can be attributed to the rising use of targeted panels and their efficiency in identifying cancer tumors.
  • Based on the application, the screening segment dominated the U.S. clinical oncology NGS market with a revenue share of 80.6% in 2022, owing to the growing prevalence of cancer disorder across the country.
  • Based on the end-use, the laboratories segment accounted for the largest share of 64.4% in the U.S. clinical oncology NGS market in 2022. This dominance of the segment is due to the rising research and development activities for cancer treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Reduction in costs for genetic sequencing
      • 3.2.1.2. Advances in the field of personalized medicine
      • 3.2.1.3. Increase in prevalence of cancer
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of computational efficiency for data management
  • 3.3. Industry Analysis Tools
    • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 4.1. U.S. clinical Oncology NGS Market: Technology Movement Analysis
  • 4.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Sequencing & Resequencing
    • 4.5.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 5.1. U.S. clinical Oncology NGS Market: Workflow Movement Analysis
  • 5.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
  • 5.3. 5 NGS Pre-Sequencing
    • 5.3.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
  • 5.4. NGS Sequencing
    • 5.4.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
  • 5.5. NGS Data Analysis
    • 5.5.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 6.1. U.S. clinical Oncology NGS Market: Application Movement Analysis
  • 6.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 6.3. Screening
    • 6.3.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.2. Sporadic Cancer
      • 6.3.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.3. Inherited cancer
      • 6.3.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.4. Companion Diagnostics
    • 6.4.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.5. Other Diagnostics
    • 6.5.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

  • 7.1. U.S. clinical Oncology NGS Market: End Use Movement Analysis
  • 7.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Clinics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.5. Laboratories
    • 7.5.1. Laboratories U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Illumina, Inc.
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. F. Hoffmann-La Roche Ltd
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Agilent Technologies, Inc.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Myriad Genetics, Inc.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Beijing Genomics Institute (BGI)
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. QIAGEN
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Perkin Elmer, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. PacBio
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Oxford Nanopore Technologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. PerkinElmer Inc
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Macrogen, Inc
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives

List of Tables

  • TABLE 1. Cancer Incidence and Mortality, 2018
  • TABLE 2. U.S. clinical Oncology NGS Market estimates & forecasts
  • TABLE 3. U.S. clinical Oncology NGS Market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • TABLE 4. U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • TABLE 5. U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 6. U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Penetration & growth prospect mapping for application, 2022
  • Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
  • Fig. 14 Cost per genome
  • Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
  • Fig. 16 Number of new cancer cases in the World, 2022
  • Fig. 17 Market restraint relevance analysis (Current & future impact)
  • Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 19 Porter's Five Forces Analysis
  • Fig. 20 Strategy framework
  • Fig. 21 Participant categorization
  • Fig. 22 U.S. clinical oncology NGS market: Technology outlook key takeaways
  • Fig. 23 U.S. clinical oncology NGS market: Technology movement analysis
  • Fig. 24 Whole genome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 25 Whole exome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 26 Targeted sequencing and resequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. clinical oncology NGS market: Workflow outlook key takeaways
  • Fig. 28 U.S. clinical oncology NGS market: Workflow movement analysis
  • Fig. 29 NGS pre-sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 30 NGS sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 31 NGS data analysis for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. clinical oncology NGS market: Application outlook key takeaways
  • Fig. 33 U.S. clinical oncology NGS market: Application movement analysis
  • Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 35 Sporadic cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 36 Lifetime cancer risks for common cancers
  • Fig. 37 Inherited cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 38 Companion diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 39 Other diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 41 Key companies profiled